Ligand Pharmaceuticals (LGND) Amortization - Intangibles (2015 - 2026)

Ligand Pharmaceuticals (LGND) has 12 years of Amortization - Intangibles data on file, last reported at $8.1 million in Q1 2026.

• For the quarter ending Q1 2026, Amortization - Intangibles fell 1.94% year-over-year to $8.1 million; the trailing twelve-month figure through Mar 2026 stood at $32.5 million (down 1.61% YoY), and the FY2025 full-year result was $32.7 million, down 0.91% from the prior year.
• Amortization - Intangibles was little changed at $8.1 million in Q1 2026, from $8.1 million in the prior quarter.
• In the past five years, Amortization - Intangibles ranged from a high of $8.6 million in Q1 2022 to a low of $8.1 million in Q4 2025.
• A 5-year average of $8.3 million and a median of $8.3 million in 2024 frame the typical range for Amortization - Intangibles.
• Peak annual rise in Amortization - Intangibles reached 830.45% in 2022, while the deepest fall reached 27.56% in 2022.
• Tracing LGND's Amortization - Intangibles over 5 years: stood at $8.5 million in 2022, then retreated by 2.35% to $8.3 million in 2023, then slipped by 0.47% to $8.3 million in 2024, then declined by 2.54% to $8.1 million in 2025, then rose by 0.11% to $8.1 million in 2026.
• Business Quant data shows LGND's Amortization - Intangibles at $8.1 million in Q1 2026, $8.1 million in Q4 2025, and $8.1 million in Q3 2025.